21st August 2018: A new chapter in the provision of advanced cancer care in the North-East of England has started with the official opening of the Rutherford Cancer Centre North East.
8th August 2018: The provision of advanced cancer treatment in the South of England passed a key milestone today with the arrival of the first high energy proton beam therapy system in the region.
7th August 2018: The first patient to be treated with high energy proton beam therapy for breast cancer in the UK commenced treatment this week at the Rutherford Cancer Centre South Wales.
11th April 2018: Proton Partners International announced today it has treated the first patient in the UK with high energy proton beam therapy.
20th March 2018: Proton Partners International has been granted formal technical and regulatory approval from Healthcare Inspectorate Wales to begin treating patients with proton beam therapy at its Rutherford Cancer Centre in Wales.
12th March 2018: IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed three new contracts with Proton Partners International, to install three Proteus®ONE* compact proton therapy solutions across the UK.
7th March 2018: Wales has shown ‘outstanding’ vision in helping to develop innovative proton beam therapy services for cancer patients.
22nd February 2018: Proton Partners International and Ion Beam Applications (IBA) Group, the world’s leading developers of high energy proton beam therapy centres and systems, have officially completed testing on the UK’s first high energy proton beam machine, the Proteus®ONE.
6th February 2018: The first proton beam therapy system to be installed in the North-East of England was delivered today by Proton Partners International Ltd.
Proton beam therapy centre heralds new era for cancer care in North-East
A new chapter in the provision of advanced cancer care in the North-East of England has started with the official opening of the Rutherford Cancer Centre North East.
The centre at Bomarsund currently provides a full range of conventional cancer treatments such as radiotherapy, chemotherapy, immunotherapy, imaging and diagnostics and will offer high energy proton beam therapy.
Mike Moran, chief executive officer of Proton Partners International, said: “We are delighted to be working with the world’s leading technology partners to ensure that our centres are equipped with the most advanced technology available in cancer care. We offer a full range of cancer treatments as well as proton beam therapy which we are particularly proud to be bringing to the North East.”
The Rutherford Cancer Centre South Wales was the first clinic in the country to treat a patient with high energy proton beam therapy and patients are now travelling from across the UK and abroad for treatment there.
Mr. Moran said: “Each Rutherford Cancer Centre will bring around £20million in additional revenue to the local region through the construction and running of each, as well as the employment opportunities a centre of this kind affords. Wherever possible, we sourced all materials for the centre’s completion locally, and we see this centre as being an integral part of the community for those who need access to high quality cancer treatment.”
Professor Karol Sikora, chief medical officer of Proton Partners International, said: “The opening of our second all-encompassing cancer centre will deliver significant benefit to cancer treatment in the UK.
“This centre will help transform lives and will mean that more patients who need proton beam therapy will not have to travel abroad in future to receive it."
Proton Partners International is currently building two further UK centres in Reading and Liverpool. Other sites are also under consideration and it is the company’s aim to have a Rutherford Cancer Centre within 90 minutes of 75% of the UK population by 2021. All centres will offer proton beam therapy available to medically-insured private patients and self-paying patients, as well as NHS patients should the Rutherford Cancer Centres be commissioned to provide proton beam therapy for them.